P10636 |
TAU_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10636 |
TAU_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P10636 |
TAU_HUMAN |
Mild neurocognitive disorder [ICD-11: 6D71] |
P10636 |
TAU_HUMAN |
Choreiform disorder [ICD-11: 8A01] |
P10636 |
TAU_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P10636 |
TAU_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P10636 |
TAU_HUMAN |
Neurodegenerative disorder [ICD-11: 8A20-8A23] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
O95398 |
RPGF3_HUMAN |
Epidermal dysplasias [ICD-11: EK90] |
Q03431 |
PTH1R_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
Q03431 |
PTH1R_HUMAN |
Hypo-parathyroidism [ICD-11: 5A50] |
Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
Q13148 |
TADBP_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q13148 |
TADBP_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
Q96KQ7 |
EHMT2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q96KQ7 |
EHMT2_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
Q96KQ7 |
EHMT2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |